Monoclonal antibodies for prophylactic and therapeutic use against viral infections.

Neutralizing antibodies play an essential part in antiviral immunity and are instrumental in preventing or modulating viral diseases. Polyclonal antibody preparations are increasingly being replaced by highly potent monoclonal antibodies (mAbs). Cocktails of mAbs and bispecific constructs can be used to simultaneously target multiple viral epitopes and to overcome issues of neutralization escape. Advances in antibody engineering have led to a large array of novel mAb formats, while deeper insight into the biology of several viruses and increasing knowledge of their neutralizing epitopes has extended the list of potential targets. In addition, progress in developing inexpensive production platforms will make antiviral mAbs more widely available and affordable.
AuthorsLeonard Both, Ashley C Banyard, Craig van Dolleweerd, Edward Wright, Julian K-C Ma, Anthony R Fooks
JournalVaccine (Vaccine) Vol. 31 Issue 12 Pg. 1553-9 (Mar 15 2013) ISSN: 1873-2518 [Electronic] Netherlands
PMID23370150 (Publication Type: Journal Article, Review)
CopyrightCrown Copyright © 2013. Published by Elsevier Ltd. All rights reserved.
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Antiviral Agents
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Neutralizing (immunology)
  • Antibodies, Viral (immunology)
  • Antibody Specificity
  • Antiviral Agents (therapeutic use)
  • Humans
  • Immunization, Passive
  • Protein Engineering
  • Virus Diseases (prevention & control, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: